Attached files

file filename
EX-7.1 - KIWA BIO-TECH PRODUCTS GROUP CORPex7-1.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 11, 2017

 

Kiwa Bio-Tech Products Group Corporation

(Exact Name of Registrant as Specified in Charter)

 

Nevada   000-33167   77-0632186

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3200 Guasti Road, Ste. 100, Ontario, CA   91761
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (626) 715-5855

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)

 

 

 

 
 

 

EXPLANATORY NOTE

 

The sole purpose of this Amendment is to file correspondence from the Company’s prior Certifying Accountant which was received following the filing of the Form 8-K as Exhibit 7.1

 

 
 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

7.1 Letter from DYH & Company addressed to the U.S. Securities and Exchange Commission dated October 13, 2017.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 13, 2017

 

  Kiwa Bio-Tech Products Group Corporation
     
    /s/ Yvonne Wang
  By: Yvonne Wang
  Title: Chief Executive Officer